M
Marc A. Shuman
Researcher at University of California, San Francisco
Publications - 133
Citations - 10597
Marc A. Shuman is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Platelet & Thrombin. The author has an hindex of 54, co-authored 133 publications receiving 10294 citations. Previous affiliations of Marc A. Shuman include University of California & Hospital of the University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation.
TL;DR: It is demonstrated that GMP-140 is an alpha-granule membrane protein that is expressed on the platelet plasma membrane during degranulation.
Journal ArticleDOI
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption.
James L. Rubenstein,Jin Kim,Tomoko Ozawa,Michael Zhang,Manfred Westphal,Dennis F. Deen,Marc A. Shuman +6 more
TL;DR: It is demonstrated that inhibition of VEGF significantly prolongs survival in athymic rats inoculated in the basal ganglia with G55 human glioblastoma cells and systemic anti-VEGF inhibition causes decreased tumor vascularity as well as a marked increase in tumor cell apoptosis in intracranial tumors.
Journal ArticleDOI
Prevention of metastasis by inhibition of the urokinase receptor
TL;DR: The results indicate that cell surface u-PA activity is essential to the metastatic process and the assay system employed in these experiments may be generally useful in testing other therapeutic modalities to limit the spread of primary tumors.
Journal ArticleDOI
Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment
James L. Rubenstein,Dan Combs,Jay Rosenberg,Arthur Levy,Michael P. McDermott,Lloyd E. Damon,Robert J. Ignoffo,Kenneth Aldape,Arthur Shen,Dana Lee,Antonio J. Grillo-Lopez,Marc A. Shuman +11 more
TL;DR: In this article, the authors conducted an analysis of the safety and pharmacokinetics of direct intrathecal administration of rituximab using cynomolgus monkeys and found that drug clearance from the CSF is biphasic, with a terminal half-life of 4.96 hours.
Journal ArticleDOI
Phase I Study of Intraventricular Administration of Rituximab in Patients With Recurrent CNS and Intraocular Lymphoma
James L. Rubenstein,Jane Fridlyand,Lauren E. Abrey,Arthur Shen,Jon Karch,Endi Wang,Samar Issa,Lloyd E. Damon,Michael D. Prados,Michael T. McDermott,Joan M. O'Brien,Christopher M. Haqq,Marc A. Shuman +12 more
TL;DR: In this article, the authors conducted a phase I dose-escalation study of intrathecal rituximab monotherapy in patients with recurrent CNS non-Hodgkin's lymphoma (NHL).